Portal de Periódicos da CAPES

Acute Immune Signatures and Their Legacies in Severe Acute Respiratory Syndrome Coronavirus-2 Infected Cancer Patients

2021; Cell Press; Volume: 39; Issue: 2 Linguagem: Inglês

10.1016/j.ccell.2021.01.001

1878-3686

Sultan Abdul-Jawad, Luca Baù, Thanussuyah Alaguthurai, Irene del Molino del Barrio, Adam G. Laing, Thomas S. Hayday, Leticia Monin, Miguel Muñoz‐Ruiz, Louisa McDonald, Isaac Francos-Quijorna, Duncan R. McKenzie, Richard Davis, Anna Lorenc, Julie Chan, Sarah Ryan, Eva Bugallo-Blanco, Rozalyn Yorke, Shraddha Kamdar, Matthew Fish, Iva Zlatareva, Pierre Vantourout, A.R. Jennings, Sarah Gee, Katie J. Doores, Katharine Bailey, Sophie Hazell, Julien de Naurois, Charlotte Moss, Beth Russell, Aadil Khan, Mark Rowley, Reuben Benjamin, Deborah Enting, Doraid Alrifai, Yin Wu, You Zhou, Paul R. Barber, Tony Ng, James Spicer, Mieke Van Hemelrijck, Mayur Kumar, Jennifer Vidler, Yadanar Lwin, Paul Fields, Sophia N. Karagiannis, A C C Coolen, Anne Rigg, Sophie Papa, Adrian Hayday, Piers Patten, Sheeba Irshad,

SARS-CoV-2 and COVID-19 Research

Given the immune system's importance for cancer surveillance and treatment, we have investigated how it may be affected by SARS-CoV-2 infection of cancer patients. Across some heterogeneity in tumor type, stage, and treatment, virus-exposed solid cancer patients display a dominant impact of SARS-CoV-2, apparent from the resemblance of their immune signatures to those for COVID-19+ non-cancer patients. This is not the case for hematological malignancies, with virus-exposed patients collectively displaying heterogeneous humoral responses, an exhausted T cell phenotype and a high prevalence of prolonged virus shedding. Furthermore, while recovered solid cancer patients' immunophenotypes resemble those of non-virus-exposed cancer patients, recovered hematological cancer patients display distinct, lingering immunological legacies. Thus, while solid cancer patients, including those with advanced disease, seem no more at risk of SARS-CoV-2-associated immune dysregulation than the general population, hematological cancer patients show complex immunological consequences of SARS-CoV-2 exposure that might usefully inform their care.